Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 2012, with the announcement dated September 7, 2012. The filing details a corporate action regarding the 3.00% Convertible Senior Notes due 2018 issued by GSK's wholly owned subsidiary, Human Genome Sciences Inc. (HGS), following GSK's acquisition of HGS.
Key Financial Metrics
The filing does not provide standard operating financial metrics such as revenue, profit, cash flow, margins, or overall debt levels. The financial data presented is specific to the HGS convertible notes:
- Notes Outstanding: $214,000 principal amount remains outstanding.
- Previously Converted: $494,286,000 principal amount has already been converted.
- Conversion Consideration: During the temporary increase period, holders receive $1,241.48 in cash per $1,000 principal amount converted.
- Conversion Rate: Temporarily increased to 87.1211 (from the standard 75.0469).
Material Changes
The primary material change is the temporary increase in the conversion rate for the HGS 3.00% Convertible Senior Notes. This change applies to conversions occurring between September 24, 2012, and October 23, 2012. Following GSK's cash acquisition of HGS, the notes are convertible solely into cash rather than equity. The filing notes that the notes were not convertible prior to this specific "Increase Period" and will not be convertible again until conditions in the indenture are met, potentially not before August 15, 2018.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or operational outlook for GSK. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties. Specific factors affecting operations are referenced in the "Risk factors" section of GSK's 2011 Annual Report on Form 20-F. No unusual items or contingencies beyond the note conversion mechanics are disclosed.
Investor Verification Checklist
- Verify the exact timing of the "Increase Period" (September 24 to October 23, 2012) to determine eligibility for the enhanced conversion rate.
- Confirm the remaining principal amount of $214,000 and the cash payout calculation of $1,241.48 per $1,000 note.
- Review the indenture conditions to understand when the notes may become convertible again after the Increase Period expires.
- Check the 2011 Annual Report on Form 20-F for detailed risk factors referenced in this filing.